Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
On Thursday, Eli Lilly and Co. LLY said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.The moves underscore growing competition with Danish rival Novo Nordisk A/S NVO in the lucrative obesity drug market.Starting in September, Lilly will raise the U.K. list price for Mounjaro’s highest monthly dose from 122 pounds to 330 pounds, a 170% jump, bringing it in line with prices in other European markets.Also Read: Eli Lilly Strikes ...